1153 results about "Gene expression" patented technology

The invention belongs to the field of agricultural chemistry and bio-fertilizer, and discloses a fertilizer synergist based on polyaspartic acid, alginate oligosaccharide and mannan oligosaccharide and a preparation method of the fertilizer synergist. According to the synergist, polyaspartic acid derived from plant source amino acid, alginate oligosaccharide extracted from natural brown algae and mannan oligosaccharide extracted from plants are used as main raw materials, and the polyaspartic acid, the alginate oligosaccharide and the mannan oligosaccharide cooperate to form an induction-complexation-adsorption three-effect-in-one mechanism, wherein the alginate oligosaccharide and the mannan oligosaccharide induce plant root activity and stress resistance gene expression; the polyaspartic acid is dominated to form a multi-point weak complex network, so that slow release and controlled release of nitrogen and potassium ions are realized; the three components cooperate on the surface of soil colloid to form an adsorption layer, and nutrient leaching loss is reduced. The preparation process adopts a green process of'enzymatic pretreatment-segmented complexing-low-temperature forming ', so that the oligosaccharide activity is maintained, and the use of an organic solvent is avoided. The obtained synergist can significantly improve the nitrogen utilization rate and the root activity and prolong the fertilizer efficiency period, and is suitable for green and efficient agricultural production of various crops.

The invention discloses a novel application of an RNF6 gene, namely, an application of screening a medicine for preventing and / or treating Zika virus infection, aiming at inhibiting expression of the RNF6 gene or knocking out the RNF6 gene. A series of functional experiments prove that the RNF6 gene promotes the replication of the Zika virus, and the purpose of reducing the replication of the Zika virus can be achieved by using an expression inhibitor of the RNF6 gene or knocking out the RNF6 gene; experimental results show that the RNF6 gene can be used as a potential target for preventing and / or treating Zika virus infection, and a new direction is provided for development of drugs for preventing and / or treating Zika virus infection targeting the RNF6 gene in the future.

The invention provides an hpRNA interference vector for laver and application of the hpRNA interference vector, and belongs to the technical field of genetic engineering and algae biology. According to the hpRNA interference vector, a binary vector pBI121 is used as a skeleton vector, a laver endogenous Actin promoter and a multiple cloning site segment are inserted, the multiple cloning sites allow target gene segments to be cloned in a forward and reverse repetition mode, the target gene segments are spaced by introns, and therefore an efficient hpRNA structure is formed after transcription, and the efficient hpRNA interference vector is obtained. The gene can be directly used for silencing important genes related to growth and development, metabolic regulation, stress response and the like in the laver. The invention further provides a construction method of the hpRNA interference vector and application of the hpRNA interference vector in silencing laver genes and provides a method for silencing laver gene expression, the gene silencing effect is remarkable, experimental results can be repeated, and a powerful tool is provided for molecular breeding and genetic improvement of laver.

The invention relates to the technical field of biology, in particular to application of a biological product expressed by an EsPTI15 gene to regulation and control of tiller number. The nucleotide sequence of the EsPTI15 gene is shown as SEQ ID NO: 1, it is found for the first time that the tiller number of EsPTI15 gene overexpressed siberian wildrye is remarkably increased compared with wild siberian wildrye, and the result proves that overexpression of the EsPTI15 gene can positively regulate and control the plant tiller development process. The discovery not only enriches the molecular mechanism theory of plant tillering regulation, but also verifies that the EsPTI15 gene has the application potential of increasing the tillering number of the plant, and provides key theoretical support and gene resources for subsequent technical research and development of introducing the EsPTI15 gene through gene operation, increasing the tillering number of forage grass and further realizing biomass improvement.

The present application relates to the field of bioinformatics. In particular, the present application relates to methods and apparatus for speculating variable splicing functionality based on single cell transcriptome data. The method comprises the following steps: determining a variable splicing mode of each gene in a data set in a cell; determining the incidence relation between the variable splicing mode and the gene expression of each gene; a variable splicing mode module is determined according to the incidence relation between the variable splicing modes and the gene expression, and the variable splicing mode module is a variable splicing mode set obtained through clustering according to the correlation between the variable splicing modes and the cell phenotypes; displaying the cell splicing heterogeneity according to the variable splicing mode module; and / or determining a potential regulatory mechanism between the variable splicing mode and the gene expression according to the variable splicing mode module, the potential regulatory mechanism being used for embodying key splicing factors in the gene expression, and a biological approach in which the variable splicing mode affects the cell phenotype.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The invention discloses a Bordetella pertussis strain subjected to genetic intervention as well as a preparation method and application of the Bordetella pertussis strain. Compared with the Bordetella pertussis strain BAA-589, the Bordetella pertussis strain disclosed by the invention has the advantage that the Bordetella pertussis strain has an element for reducing the expression of the BP1569 gene. The bordetella pertussis strain provided by the invention has the effect of obviously increasing the yield of OMV, and has a good application prospect in promoting the development of bordetella pertussis OMV vaccines.

The invention discloses dsRNA of a targeted BdSpt7 gene, a biocontrol agent and application of the dsRNA. The sequence of the dsRNA of the targeted BdSpt7 gene is as shown in SEQ ID No.2. The invention further discloses a preparation method of the biocontrol agent of the targeted BdSpt7 gene. The active ingredient of the biocontrol agent is the dsRNA of the target BdSpt7 gene. The invention also provides an application of the botryosphaeria dothidea BdSpt7 gene in prevention and treatment of apple botryosphaeria dothidea, and a nucleotide sequence of the botryosphaeria dothidea BdSpt7 gene is shown as SEQ ID No.1. The invention also provides an African trichoderma harzianum engineering strain for expressing dsRNA, the African trichoderma harzianum engineering strain is integrated with a dsRNA expression box for interfering gene expression of a target gene BdSpt7, the dsRNA expression box is shown as SEQ ID No.1, and the African trichoderma harzianum is an African trichoderma harzianum with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No. 41709. The dsRNA targeting the BdSpt7 gene can significantly reduce the pathogenicity of the physalospora piricola through interference, and the African trichoderma harzianum engineering strain can colonize on the plant surface and continuously express the dsRNA so as to play a role in preventing and treating the physalospora piricola, and is green and environment-friendly.

The invention belongs to the technical field of synthetic biology, and particularly relates to recombinant escherichia coli for efficiently producing O-acetyl-L-homoserine as well as a construction method and application of the recombinant escherichia coli. According to the invention, CRISPR-Cas9 gene editing is combined with metabolic modification, so as to precisely integrate OAH biosynthesis key nodes: introducing and overexpressing a mutant metX gene at a genome pseudogene site to enhance the expression of homoserine acetyltransferase, knocking out byproducts such as poxB and mgsA to synthesize genes, and carrying out high-yield synthesis of OAH. Corynebacterium glutamicum thrA (anti-feedback inhibition), aspB and bacillus subtilis acsA-acuA genes (construction of an acetic acid switch) are introduced, gene expression of gltA, tpiA and the like is optimized to increase supply of precursors such as acetyl CoA and the like, and finally a stable strain without plasmids, antibiotics and inducers is obtained. The production cost is effectively reduced, and the method has the advantage of high genetic stability and shows a good application prospect in OAH industrial production.

Provided are an siRNA which inhibits plasma coagulation factor XI gene expression, a pharmaceutical composition containing the siRNA, a conjugate, a reagent kit, and a use of the siRNA, the pharmaceutical composition thereof and the conjugate in preparing a drug used for treating and / or preventing thrombotic diseases and ischemic strokes.

The present disclosure provides a method for producing a polyisoprenoid, which makes it possible to synthesize in vitro a polyisoprenoid having an unprecedented structure, such as a 100% cis-polyisoprenoid or a polyisoprenoid containing an allylic diphosphate derivative as an initiating terminal. The present disclosure relates to a method for producing a polyisoprenoid in vitro, which employs a gene coding for a neryl diphosphate synthase and rubber particles bound to a protein encoded by the gene, or a method for producing a polyisoprenoid, which includes introducing into a plant a vector in which a gene coding for a neryl diphosphate synthase is linked to a promoter having a promoter activity that drives laticifer-specific gene expression to express a protein encoded by the gene specifically in laticifers.

The invention provides a precise magnetic control whole blood rare cell flow magnetic separation system, a magnetic separation and identification method and application, and belongs to the technical field of micro-control flow biological detection. According to the invention, the magnetic separation chip can form a gradient magnetic field, and cells are fixed at a certain position on the sealing film under the combined action of magnetic field force and friction force, so that the separation of the cells is realized. Whole blood cell detection is carried out based on the gradient magnetic field, whole blood sample loading treatment can be directly carried out, the problem that the capture rate is reduced due to mechanical death, damage and stress gene expression caused by repeated elution / transfer steps is avoided, and the capture efficiency and cell activity of the chip are guaranteed; the magnetic field provided by electricity is not needed, the cost is low, the detection accuracy is high, the problems existing in existing CTC detection are solved, economic and practical values are achieved, further development of CTC detection can be promoted, and a novel and effective method is provided for complete blood cell separation detection.

The invention discloses a composition for regulating sleep rhythm homeostasis as well as a preparation method and application thereof. The composition for regulating the sleep rhythm homeostasis is prepared from the following components in percentage by weight: 5 to 18 percent of polydextrose, 9 to 15 percent of galactooligosaccharide, 1 to 10 percent of inulin, 0.4 to 2 percent of gamma-aminobutyric acid, 0.8 to 2.2 percent of L-theanine, 0.1 to 3.5 percent of magnesium citrate, 2 to 21 percent of semen ziziphi spinosae extract, 1 to 10 percent of poria cocos extract, 0.5 to 2 percent of pericarpium citri reticulatae extract, 0.3 to 1 percent of liquorice root extract and 15 to 40 percent of maltodextrin. 5-18% of coconut oil powder MCTs, and 0.5-2% of a lily extract. According to the application, a magnesium MCTs shell-core structure is delivered by maltodextrin to form a mitochondrial piezoelectric engine so as to improve prebiotics, promote flora metabolism efficiency and energy supply feedback, activate intestinal pheochromophilic cells and improve SLC6A4 gene expression so as to improve synthesis of 5-hydroxytryptamine in the brain and activate GABA energy neurons; meanwhile, through the spina date seed and poria cocos quantum dots and a pericarpium citri reticulatae and liquorice pi-pi stacking network, the blood-brain barrier penetration rate is greatly increased, and hypothalamic CRH release is adjusted.

The present disclosure provides siRNAs, modifiers, conjugates and uses thereof for targeted regulation of Factor 11 of coagulation (FXI) gene expression. A series of siRNAs are designed based on an FXI messenger ribonucleic acid (mRNA) sequence, alternate modification is carried out, and modification is carried out by utilizing a group of specific modification templates. Cellular and animal experiment results show that some alternately modified and specific template modified oligonucleotide sequences can significantly inhibit the expression of the FXI gene, and can be used for developing anticoagulant drugs.

The invention provides a space transcriptomics organization space domain intelligent identification method based on a Graph Transform. The method comprises the following steps: reading a space transcriptomics data file; extracting features in the histological image data by adopting a pre-trained deep learning model; setting a spatial distance threshold value; acquiring spatial position data of each sampling point according to a set spatial distance threshold value, and constructing an adjacent matrix; combining the gene expression data, the adjacent matrix and the histological image features to obtain a normalized feature matrix; performing dimensionality reduction on the normalized feature matrix by adopting PCA; inputting the feature matrix subjected to dimension reduction processing into a feature learning model to obtain a comprehensive feature representation; clustering the obtained feature representations by adopting a Leiden algorithm to obtain a spatial domain classification result; according to the invention, deep fusion of multi-modal information is realized through a Graph Transform architecture, spatial distribution rules and functional characteristics of cells can be captured at the same time, and a systematic solution is provided for analyzing a complex structure of a tissue microenvironment.

The invention relates to a strong promoter P7 suitable for streptomyces and application thereof, and relates to the field of genetic engineering and microbial metabolism engineering. The nucleotide sequence of the strong promoter P7 is as shown in SEQ ID No.1, and the strong promoter comprises a plasmid vector of the strong promoter; a host cell comprising the plasmid vector; the invention also discloses application of the strong promoter, the plasmid vector and the host cell in starting expression of a target gene. Compared with the prior art, the characterization of the strong promoter P7 provides an effective tool element for streptomyces strong promoter engineering and high-efficiency gene expression, and has important significance on streptomyces silent gene characterization, high-efficiency gene expression, metabolite synthesis, metabolic pathway reconstruction and the like. The strong promoter can be applied to common streptomyces type strains, and has important significance on high yield of important proteins including enzymes and important metabolites from actinomycetes.

Provided herein are methods of detecting an analyte of interest to interrogate spatial gene expression in a sample using RNA-templated ligation.

The present invention relates to an siRNA for inhibiting FXI gene expression, an siRNA conjugate, a pharmaceutical composition containing same, and the use thereof. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide, and the siRNA contains a sense strand and an antisense strand. The siRNA and the conjugate and pharmaceutical composition thereof can effectively treat and / or prevent diseases associated with FXI gene overexpression.

The invention discloses a composition for preventing and treating eggplant root rot, and relates to the technical field of biological prevention and treatment. The composition consists of three parts, namely a double-stranded RNA (Ribonucleic Acid) delivery body controlled by a kaolinite nanotube-metal polyphenol network-boric acid ester, a nitric oxide / hydrogen sulfide double-pulse microcapsule and volatile organic compound particles of beta-cyclodextrin cross-linked aerogel, wherein the three parts are matched according to the total mass ratio of 1: (0.8-1.5): (0.8-1.2). Through structural design, time sequence release of non-overlapping peak values is realized, and a prevention and control mode for inhibiting environment enhancement host precise silencing is formed. The deliverer can be selectively disintegrated under the condition of pathogen-induced organic acid, iron chelating agent and hydrogen peroxide, so that the targeted release of the double-stranded RNA is realized; the double-pulse microcapsule respectively releases nitric oxide and hydrogen sulfide in a transplanting stress stage and an early disease stage, and induces host defensive gene expression; the aerogel particles continuously release 2, 3-butanediol and aromatic aldehyde to inhibit germination of pathogenic bacteria and serve as rhizosphere signals to enhance host resistance.

The invention discloses a recombinant adeno-associated virus vector for targeted delivery of VEGF-C (vascular endothelial growth factor-C) and application of the recombinant adeno-associated virus vector in promoting endocardial differentiation to treat coronary heart disease. The rAAV vector comprises transgene for coding VEGF-C protein or VEGF-C protein functional variant and a tissue-specific promoter operably connected to the transgene, wherein the tissue specific promoter is capable of driving the transgene to be specifically expressed in the heart endothelial cells. According to the treatment method developed by the invention, specific expression of the Vegfc gene in the heart is driven by using an ICAM2 promoter with targeting to endothelial cells, and a remarkable curative effect is shown in a myocardial infarction model mouse. The therapeutic scheme provides a new effective strategy for intervention and treatment of myocardial infarction and chronic heart failure, and has the advantages of high safety, long gene expression duration, extremely low immune response to a host and the like.

The invention relates to the field of gene engineering, in particular to Os HSL mutants and coding genes, expression vectors, transgenic cells, compositions and application thereof, the mutants are Os HSL1 enzyme and / or Os HSL2 enzyme mutants, the amino acid sequence of the Os HSL1 enzyme is as shown in SEQ ID NO.1, and the amino acid sequence of the Os HSL2 enzyme is as shown in SEQ ID NO.2. The invention further relates to an application of the Os HSL mutants and the coding genes, the expression vectors, the transgenic cells and the compositions. The invention relates to a gene, a protein, a carrier, a cell and a composition which endow plants with a detoxification effect on an HPPD inhibitor and application of the gene, the protein, the carrier, the cell and the composition to plant improvement, so that the plants are endowed with resistance to the HPPD inhibitor.

SpRYc is a grafted ScCas9++-SpRY chimeric Cas9 possessing minimal 5′-NNN-3′ PAM specificity. SpRYc comprises the N-terminus (residues 1-1119) of ScCas9++ (Sc++), including the flexible loop, followed by the region of SpRY (residues 1111-1368) spanning its PAM-interacting domain mutations. Methods of altering gene expression include use of SpRYc in complex with guide RNA in a CRISPR-Cas9 system.

The invention relates to the field of cosmetics, in particular to dendrobium devonianum stem extract as well as a preparation method and application thereof. The invention provides a dendrobium devonianum stem extract. The mass ratio of glucose to mannose in the dendrobium devonianum stem extract is 3: 7. The invention provides the dendrobium devonianum stem extract with tightening and moisturizing functions, and the extract can effectively inhibit ROS secreted by UVB-induced in-vitro keratinocytes at a lower concentration, and has a certain tightening effect; the AQP3 level in keratinocytes is improved, the AQP3 gene expression is up-regulated, and a certain moisturizing effect is achieved; the dendrobium devonianum stem extract is used for a formula human body efficacy test, and it is proved that 0.1% of the dendrobium devonianum stem extract has certain tightening and moisturizing effects.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as small interfering RNA (siRNA) molecules, able to inhibit proprotein convertase subtilisin kexin 9 (PCSK9) gene expression. Also disclosed are pharmaceutical compositions that include PCSK9 RNAi agents and methods of use thereof. The PCSK9 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the PCSK9 RNAi agents in vivo provides for in vivo provides for inhibition of PCSK9 gene expression and thereby reduction of PCSK9 protein. The RNAi agents can be used in methods of treatment of diseases or disorders mediated at least in part by PCSK9 gene expression, including among others hypercholesterolemia, familial hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), familial hypobetalipoproteinemia, hyperlipidemia, coronary artery disease, polygenic dyslipidemia, heart disease, cardiovascular disease (CVD) including clinical atherosclerotic cardiovascular disease (ASCVD).

Provided is an RNA inhibitor inhibiting PCSK9 gene expression, comprising an antisense strand, the antisense strand comprising a complementary region complementary to at least a portion of mRNA encoding PCSK9, and the length of the complementary region being 17-23 nucleotides; the antisense strand comprises any one of the following nucleotide sequences: SEQ ID NO.: 328-654, 1045-1107, 1125-1146 or 1149-1170, or a sequence differing therefrom by no more than 3 nucleotides. Also provided is a pharmaceutical composition, comprising the described RNA inhibitor inhibiting PCSK9 gene expression, and further comprising a delivery medium, and / or a pharmaceutically acceptable excipient and / or carrier and / or diluent.

The disclosure describes changes in cfRNA gene expression that are associated with risk for preeclampsia. Accordingly, the disclosure provides methods and kits for preeclampsia risk assessment.

The invention discloses liver peptide capable of protecting liver and improving asthenopia as well as a preparation method and application of the liver peptide, and belongs to the technical field of biology. The liver peptide contains at least one of DAIP, SPF, DIAP, SLP, AVGP or NLP, and the prepared liver peptide has multiple physiological effects: the liver peptide can effectively activate ADH enzyme activity, reduce ALT and AST levels and protect liver cells; the lipid metabolism is improved by regulating and controlling the expression of the SREBP-1c, the FAS and the PPAR-alpha genes; meanwhile, the antioxidant capacity is remarkable, the ROS level can be reduced, and the SOD content and the CAT content can be increased; the expression of RPE65 and LRAT genes can be up-regulated, and the visual function is maintained. The method disclosed by the invention is simple in process and convenient to operate, the obtained liver peptide can be widely applied to the field of functional products for protecting the liver, improving visual fatigue and the like, and an innovative solution is provided for high-value utilization of liver resources.

One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.

The invention discloses a cellobiose 2-epimerase mutant as well as a gene, an expression vector, recombinant bacteria, a preparation method and application thereof. The mutant is obtained by performing the following point mutation on an amino acid sequence as shown in SEQ ID No.1: S12A, S24A, G131A, G176A, G224A, K46R, K69R, K72R, K91R, K103R, K201R, K219R, K223R, K241R, K263R, K266R, K273R, K284R, K325R, K335R, K349R and K387R. The invention further discloses a preparation method of the mutant. The invention further discloses a gene segment, a plasmid and a recombinant bacterium for recombinant expression of the mutant, and the gene segment, the plasmid and the recombinant bacterium are used for recombinant expression preparation of the mutant. The mutant can be used for continuously and stably catalyzing and preparing lactulose at high temperature, is relatively good in thermal stability and has a relatively good industrial application prospect.

The present disclosure provides double stranded ribonucleic acid (dsRNA) agents for inhibiting expression of a target gene, comprising an antisense strand which is complementary to the target gene; a sense strand which is complementary to the antisense strand and forms a double stranded region with the antisense strand; at least one alpha-v-beta-6 (αvβ6) integrin targeting ligand that mediates delivery to muscle tissue conjugated to at least one strand; and at least one in vivo delivery enhancing moiety conjugated to one or more internal positions on at least one strand. The present disclosure also provides compositions comprising such dsRNA agents, and methods of use thereof for treating a subject having a disorder that would benefit from reduction in expression of the target gene.